BioSpace News Archive

RISE researchers present Adult Medication Study results at the ADA’s Scientific Sessions and share the first direct comparison for youth and adult studies

Significant Time-in-Range Improvements Demonstrated in Adult and Pediatric Age Groups

REWIND data showed a consistent effect in people with and without established cardiovascular disease

Acucela Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced that the European Medicines Agency granted orphan designation to Acucela’s leading drug candidate emixustat hydrochloride for the treatment of Stargardt disease.

Once respondents become familiar with Blue Button, 83% indicated they would consider using it

CStone Pharmaceuticals announced that the company has entered into a global clinical collaboration with China focus with Bayer HealthCare LLC to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of its PD-L1 monoclonal antibody CS1001 in combination with Bayer’s regorafenib, an oral multi-kinase inhibitor, as a treatment for multiple cancers including gastric cancer.

DirecNet study indicates youth with early-onset T1D have mild but detectable differences in brain development, based on research presented at the ADA’s Scientific Sessions

Presented at ADA’s Scientific Sessions, REWIND trial confirms dulaglutide reduces CVD risk regardless of CV history

Pediatric Scientific Data for the Omnipod Horizon System Presented at the American Diabetes Association’s 79th Scientific Sessions

Sub-analysis of data from DECLARE-TIMI 58 trial shows a 47% reduction of composite kidney function decline, end-stage renal disease or death, presented today at the ADA’s Scientific Sessions